ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0807

Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
Abstract Number: 0808

Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis
Abstract Number: 0809

The Impact of Flares on Clinical and Patient Reported Outcomes in Rheumatoid and Undifferentiated Arthritis Patients
Abstract Number: 0810

Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
Abstract Number: 0811

Using a Smartphone App to Detect and Characterise Real-Time Patient-Reported Flares in Rheumatoid Arthritis
Abstract Number: 0812

Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis
Abstract Number: 0813

Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study
Abstract Number: 0814

Patient Characteristics, Efficacy, and Treatment Patterns of Tofacitinib Monotherapy in Patients with RA: Contextualization of Randomized Controlled Trial Results with Real-world Data
Abstract Number: 0815

Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID
Abstract Number: 0816

Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting
Abstract Number: 0817

Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
Abstract Number: 0818

Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Abstract Number: 0819

A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort
Abstract Number: 0820

The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Abstract Number: 0821

Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].